zeneca has submitted for approval a new drug that is likely to affect profits growth within two or three years casodex is a treatment for prostate cancer that is estimated by lehman brothers the stockbrokers to have potential sales of between dollars 250 m and dollars 500 m pounds 323 m a year that would make it zeneca's third-biggest seller the drug is an oral anti-androgen about 300,000 new prostate cancer cases are reported each year worldwide making it the second most common cancer in men approval for the drug is being sought first in the uk submissions to regulatory authorities in the rest of the european union and in the us will follow by the end of the year and it is likely to reach the market in 1995 other companies making or developing anti-androgens include schering plough and johnson johnson of the us casodex's approval would place zeneca more firmly in the cancer market it already has nolvadex and zoladex in the area but both are outsold by heart treatments zestril and tenormin